Immunomic Therapeutics to Sponsor and Present at CHCI Health Summit
ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. announced today that its’ Senior Vice President and Co-Founder, Teri Heiland, Ph.D., will participate in the closing plenary on Innovation and Technology in Healthcare at the Congressional Hispanic Caucus Initiative (CHCI) Health Summit on March 14, 2019 at 2:00 pm EST at the Newseum, Knight Conference Center in Washington, DC.
As a sponsor of the CHCI Health Summit, Immunomic Therapeutics is pleased to support the initiatives of the event which include attracting and retaining greater diversity in clinical trials, ensuring equitable health outcomes for the Latino community and considering how the latest technological innovations will support Latino’s health needs. Dr. Heiland will discuss innovation during the closing plenary session and what companies like Immunomic can do to accelerate the development and approval of novel therapies, such as Immunomic’s investigational vaccines, for illnesses that greatly affect Latinos including cancer, allergy and infectious diseases.
For more information, please visit the CHCI summit website at https://chci.org/.
ITI’s investigational UNITE platform, or UNiversal Intracellular Targeted Expression, is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in humans. In this way, ITI’s vaccines (DNA or RNA) have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body’s natural biochemistry to develop vaccines that generate broad immune responses. ITI’s UNITE platform could potentially have broad therapeutic applications in oncology, including viral antigens, cancer antigens, neoantigens and antigen-derived antibodies as biologics and ITI has built a large pipeline from UNITE with six oncology programs and two allergy programs. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit www.immunomix.com.
Source: Immunomic Therapeutics, Inc.